Efficacy and Safety of Ide-Cel Confirmed in Real-World Multiple Myeloma Population
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Adding daratumumab to lenalidomide and dexamethasone extends overall survival in relapsed/refractory multiple myeloma, according to final results from the POLLUX trial.
Researchers sought to determine whether a transplant-free regimen of KCd with carfilzomib maintenance would have similar efficacy to HSCT in multiple myeloma.
Researchers sought to determine whether the PRISM score would be able to identify patients with multiple myeloma at a high risk of VTE.
A dexamethasone-sparing treatment strategy is safe and effective for frail patients with newly diagnosed multiple myeloma, according to researchers.
Researchers sought to determine whether DNA methylation in PBMCs could be a novel biomarker in multiple myeloma.
Researchers sought to assess the geriatric assessment in hematology scale in older patients diagnosed with hematological malignancies.
Teclistamab plus daratumumab and lenalidomide produced deep and durable responses in patients with relapsed or refractory multiple myeloma.
Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.